Shamburg News · 8-K filed Nov 17, 2026, 7:50 AM EST

Allarity Therapeutics Exchanges $3M of A-1 Note for Series B Preferred; Expands Stenoparib Trial

ALLR · Allarity Therapeutics, Inc.

  • Material agreement
  • Financing
  • Other event
  • Materiality: high

On November 12, 2026, Allarity Therapeutics entered an Exchange Agreement with Streeterville Capital, partitioning a $3,000,000 note from its A-1 Note and exchanging it for 3,000 shares of Series B Preferred Stock with an aggregate initial Stated Value of $3,150,000, completed November 16, 2026. The Series B Preferred accrues a 9% preferred return, ranks senior to common stock, and is subject to covenants including a Sweep Payment of 33% of ATM net proceeds under a Side Letter. On November 16, 2026, the company also announced expanded eligibility for its Phase 2 stenoparib ovarian cancer trial.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 3.03, 5.03, 8.01, 9.01, accession 0001213900-26-121103.

Written from the filing by Shamburg Markets. Figures are as reported by the company.